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Abstract
Background: The bile salt export pump (BSEP/ABCB11) is the primary transporter for the excretion of bile acids
from hepatocytes into bile. In human, inhibition of BSEP by drugs has been related to drug-induced cholestasis and
subsequent cytotoxic effects. The role of BSEP in canine and feline liver diseases has not been studied in detail, but
the same mechanism of inhibition by drugs as in humans could play a role in veterinary medicine. The aim of this
study was to investigate the functional characteristics of feline Bsep in comparison with canine and human Bsep/
BSEP with respect to substrate affinities and inhibitory potential of model drugs. Orthologs of all three species were
cloned and cell membrane vesicles overexpressing feline, canine and human Bsep/BSEP were prepared for
functional analyses.
Results: The cDNA sequences of the open reading frames of feline, canine and human Bsep/BSEP showed a high
similarity between the species. Functional studies demonstrated for all species a tendency to a higher affinity of
BSEP/Bsep for the conjugated bile acid taurocholic acid (TCA) than glycocholic acid (GCA), and a higher affinity for
GCA than for the unconjugated cholic acid (CA). The inhibitory potency of the model inhibitors cyclosporine A,
troglitazone and ketoconazole was characterized against TCA uptake into BSEP/Bsep containing membrane vesicles.
All three substances potently inhibited TCA uptake without significant species differences.
Conclusion: Structure and functional characteristics of cat, dog and human Bsep/BSEP appeared to be very similar,
indicating that the properties of this transporter have been highly preserved among the different species. Therefore,
inhibition of BSEP by drugs could also be a mechanism in cholestasis and liver disease in veterinary relevant animal
species. This model could be used to predict drug-induced liver injury caused by BSEP inhibition at an early stage
in veterinary drug development.
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Background
An important function of the liver is the formation of
bile, which is composed of bile salts, phospholipids and
organic anions. Bile salts are amphipathic molecules that
have detergent properties and can be highly toxic to he-
patocytes if they accumulate intracellularly. Membrane-
bound transporter proteins are essential in the transport
of bile by the liver. The ATP-binding cassette (ABC)
transporter, bile salt export pump (BSEP/ABCB11), is lo-
cated in the canalicular membrane of the hepatocyte
where it actively secretes bile salts into the bile at the ex-
pense of ATP hydrolysis.
In human medicine, inhibition of ABC transporters by
drugs has been implicated in various adverse drug reac-
tions of which drug-induced liver injury has been related
to inhibition of BSEP in the liver. The inhibition of bile
acid secretion leads to high intracellular bile acid con-
centrations and subsequent cytotoxic effects [1]. The
clinical relevance of BSEP in bile salt secretion in man
has also been demonstrated by several genetic traits,
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such as progressive familial intrahepatic cholestasis type
2 (PFIC2), benign recurrent intrahepatic cholestasis (BRIC),
and intrahepatic cholestasis of pregnancy (ICP) (for review
see [2,3]).
One of the first drugs that turned out to be a BSEP in-
hibitor was troglitazone and it was withdrawn from the
market because of the development of cholestatic liver
injury [4]. To predict drug-induced liver injury caused
by BSEP inhibition at an early stage in drug development,
in vitro assays have been developed using membrane vesi-
cles from genetically engineered cells overexpressing hu-
man or rat BSEP/Bsep [5]. Several known cholestatic
drugs showed BSEP inhibition in these membrane vesi-
cles, including cyclosporine A, rifampicin and cloxacillin,
suggesting that BSEP inhibition is the mechanism behind
their hepatotoxic potential [6].
The causes and prevalence of liver diseases in dogs
and cats are mostly unknown [7], but have also been re-
lated to drugs [8,9]. The role of BSEP in canine and fe-
line liver diseases has not been studied in detail, but the
same mechanism of inhibition by drugs as in humans
could play a role in veterinary medicine. Recently, inhib-
ition of the bile salt export pump and multi-drug
resistance-associated protein (mrp) 2 by a novel kinase
inhibitor was found to be related to the development of
severe hepatotoxicity in dogs [10]. Previously, the canine
Bsep has been cloned and partly functionally character-
ized to aid the extrapolation of toxicological data from
dogs to humans [11]. However, data on feline Bsep is
completely absent.
The aim of this study was to investigate the functional
characteristics of feline Bsep in comparison with canine
and human Bsep/BSEP with respect to substrate affin-
ities and inhibitory potential of model drugs. Knowledge
about feline Bsep is lacking and therefore, this is the first
study in which the feline Bsep has been cloned and char-
acterized. As a model for in vitro cross-species extrapo-
lation of hepatotoxic data, we cloned BSEP/Bsep of all
three species and prepared cell membrane vesicles for
functional analyses.
Methods
Chemicals and reagents
Tauro [carbonyl-3H]cholic acid (TCA) (5 Ci/mmol) was
obtained from Perkin Elmer (Boston, MA). Cholic acid
[2,4-3H] (CA) (30 Ci/mmol) and glycocholic acid[glycine-
2-3H] (GCA) (40 Ci/mmol) were purchased from Biotrend
(Köln, Germany). Adenosine triphosphate (ATP), adeno-
sine monophosphate (AMP), cholic acid, cyclosporine A,
glycocholic acid, ketoconazole, taurocholic acid, troglita-
zone were purchased from Sigma Aldrich (St. Louis, MO,
USA). Bac-to-Bac and Gateway systems, Dulbecco’s modi-
fied Eagle’s medium-GlutaMAX-I culture medium and
fetal calf serum were obtained from Invitrogen (CA,
USA). Triple flasks (500 cm2) were purchased from
Sanbio BV Biological Products (Uden, The Netherlands).
RNA isolation and cDNA synthesis
Liver tissue was obtained from adult healthy European
Shorthair cats (n = 10, five males and five females, aged
approximately 1 year) and adult healthy Beagle dogs (n =
4, two males and two females, aged from 2 to 3 years) dir-
ectly after euthanasia and samples were quickly frozen in
liquid nitrogen and stored at −70°C. The cats and dogs
had served as controls in authorized studies and the ani-
mals were sacrificed with permission of the Animal Ethical
Committee and according to the Dutch law on Animal
Experiments.
RNA was isolated from 30 mg frozen liver tissue by a
spin column purification technique (SV Total RNA Iso-
lation System, Promega, Medison, USA). Aliquots of the
purified RNA were measured spectrophotometrically
and the RNA was stored at −70°C. cDNA was synthe-
sized using the protocol of the SuperScript III Reverse
Transcriptase Kit (Invitrogen, California, USA). The reac-
tion mixture, containing 1 μL of 50 μM oligo(dT)-anchor
primer or a gene specific primer (Eurogentec S.A.,
Belgium), 1μg feline RNA or 2 μg canine RNA and 1 μL
10 mM dNTP Mix (Promega, Madison, USA) in a total
volume of 13 μL, was incubated for 5 min at 65°C. Here-
after, the mixture was incubated on ice for at least 1 min
and 4 μL of 5× First-Strand buffer (250 mM Tris–HCl
pH 8.3, 375 mM KCl, 15 mM MgCl2), 1 μL of 0.1 M Di-
thiothreitol (DTT) and 400 U of SuperScript III Reverse
Transcriptase were added to a total of 20 μL reaction vol-
ume. This final mixture was incubated for 60 min at 50°C
and was inactivated by incubating it for 15 min at 70°C.
The cDNA was stored at 4°C until use.
For quantitative Polymerase Chain Reaction (PCR),
cDNA was synthesized using the protocol of iScript
cDNA Systhesis Kit (Bio-Rad, CA, USA), using 1 μg of
feline or canine RNA.
Sequence analysis
The sequence of Bsep cDNA from the canine and feline
liver samples was analyzed using canine Bsep (Abcb11)
specific primers, which were based on highly conserved
regions between human and canine BSEP/Bsep [The
National Centre for Biotechnology Information (NCBI)
accession numbers for human: NM_003742; for dog:
NM_001143932]. The primer sequences are given in
Table 1 and were produced by Eurogentec S.A. Belgium.
PCR was performed in a reaction mixture containing a final
concentration of 1× Phusion Master Mix (2× Phusion Mas-
ter Mix contained 0.04 U/μL Phusion DNA Polymerase, 2×
Phusion HF Buffer with 3.0 mM MgCl2 and 400 μM of
each dNTP) (Finnzymes, Espoo, Finland), 1 μM forward
primer, 1 μM reverse primer and 1 μL template cDNA
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Table 1 Designed primers used for PCR and DNA sequencing (Eurogentec S.A., Belgium)
Primer Sequence (5′→3′) Position (relative
to human BSEP
[NM_003742])
Oligo(dT)-anchor 5′-GACCACGCGTATCGATGTCGACTTTTTTTTTTTTTTTT
PCR-anchor 5′-GACCAGGCGTATCGATGTCGAC
BSEP_RACE_A 5′-AGTGTTGTTTGCCTGTAGC 3615-3633
BSEP_RACE_B 5′-TGAAGAAAATCGAAACAAT 273-291
BSEP_RACE_C 5′-TGTGCCAAAAATGAGGAG 367-381
BSEP_RACE_D 5′-AGTTCTTGTAATTCAGTGTCA 405-425
BSEP_Af 5′-CTCGACCTGATACGCAAGTTCTGA 3392-3415
BSEP_Ar 5′-AATGGCCCGAGCAATAGCAATAC 3805-3825
BSEP_Bf 5′-CAAGGGAAGGTGATGATAGATGG 3526-3548
BSEP_Br 5′-GATGGGGGCTCCTGTGGTAACT 4065-4086
BSEP_Cf 5′-TGTGCTTCTTCCCCTTCTTGGCT 2840-2862
BSEP_Cr 5′-TGCCCATCTATCATCACCTTCC 3530-3548
BSEP_Df 5′-CAACGCTCCAAGTCTCA 2215-2231
BSEP_Dr 5′-GTGCGGATATTACTGAG 2956-2972
BSEP_Ef 5′-CAAGGCTTGCTACGGATGC 2702-2720
BSEP_Er 5′-TGATTGGGGGTTGTCGATC 3295-3310
BSEP_Ff 5′-GTGGTGGCCAGAAACAAAG 1805-1823
BSEP_Fr 5′-TCTGGCTGAATAAAAAGGCA 2442-2461
BSEP_Gf 5′-TGGATCGAATTAAGGGTGAA 1364-1383
BSEP_Gr 5′-GCGATGAGCAACCGAAATGA 1955-1974
BSEP_Hf 5′-GATGGGATTCTTTACTGGATTC 1089-1110
BSEP_Hr 5′-CCTTCACTGGGGTCATAGAA 1537-1556
BSEP_If 5′-GCAGCTCGTCAGATACAGAA 625-644
BSEP_Ir 5′-CAGAAGGCCAATGCATAACA 1132-1151
BSEP_Jf 5′-TGAAGGCCTATGCCAAAGC 938-956
BSEP_Jr 5′-TTCACCCTTAATTCGATCCA 1364-1383
BSEP_Kf 5′-ATTGTTTCGATTTTCTTCA 273-291
BSEP_Kr 5′-GCTTTGGCATAGGCCTTCA 938-956
BSEP_Lf 5′-AACCCTTGTCCAGATTTTCCTC 1197-1218
BSEP_Lr 5′-ATGATGGGTTTCCGGTCTATTG 1313-1334
FullBsep_felinef 5′-TTGCAATTACCATGTCTGACTCAGTAATTCTTCGC
FullBsep_feliner 5′-TCAACTGATGGGGGCTCCTGTGATGACTAG
FullBsep_caninef 5′-TTGCAATTACCATGTCTGATGCAGTAATTCTTCGC
FullBsep_caniner 5′-TCAACTGATGGGGGCTCCTGTGGTAACTAG
FullBSEP + AttB1_humanf 5′-GGGGACAAGTTTGTACAAAAAAGCAGGCTTCGCCA CCATGTCTGACTCAGTAATTCTTC
FullBSEP + AttB1_humanr 5′-GGGGACCACTTTGTACAAGAAAGCTGGGTCTCAAC TGATGGGGGATCCAGTG
AttB1_felinef 5′-GGGGACAAGTTTGTACAAAAAAGCAGGCTTCGCC ACCTTGCAATTACCATGTCTGACTCAGTAATTCTTCGC
AttB1_feliner 5′-GGGGACCACTTTGTACAAGAAAGCTGGGTCTCAAC TGATGGGGGCTCCTGTGATGACTAG
AttB1_caninef 5′-GGGGACAAGTTTGTACAAAAAAGCAGGCTTCGCC ACCTTGCAATTACCATGTCTGATGCAGTAATTCTTCGC
AttB1_caniner 5′-GGGGACCACTTTGTACAAGAAAGCTGGGTCTCAAC TGATGGGGGCTCCTGTGGTAACTAG
The Oligo(dT)-anchor, PCR-anchor and the specific primer BSEP_RACE_A, were used for 3′RACE-PCR. The BSEP_Ar, Oligo(dT)-anchor, PCR-anchor, BSEP_RACE_B, C and D
were used for 5′RACE-PCR. Each primer pair is denoted with “f” for the forward primer, and “r” for the reverse primer.
van Beusekom et al. BMC Veterinary Research 2013, 9:259 Page 3 of 10
http://www.biomedcentral.com/1746-6148/9/259
in a total of 20 μL. The 3′-end and the 5′-end were ob-
tained by means of a 3′RACE-PCR and 5′-RACE-PCR re-
spectively, using a PCR-anchor primer. After an initial
denaturation at 98°C for 30 s, PCR was performed at 98°C
for 10 s, at 50-60°C for 30 s, and at 72°C for 30 s for a total
of 35 cycles, followed by a final extension of 7 min at
72°C. The PCR-products were stored at 4°C until for
further analysis.
The PCR products were separated by gel electrophor-
esis (1.2% agarose gel stained with ethidium bromide
(Bio-Rad, CA, USA)) and the cDNA was extracted and
purified from the gel by a spin column technique (Wizard
SV Gel and PCR Clean-Up System kit, Promega, Madison,
USA). The samples were further processed with the ABI
PRISM BigDye Terminatior v3.1 Ready Reaction Cycle Se-
quencing Kit (Applied Biosystems, Foster City, USA),
purified by Sephadex G-50 Superfine (Amersham Biosci-
ences, NJ, USA) and sequenced by an automated DNA se-
quencer (ABI PRISM 3130xl, Applied Biosystems). The
cDNA sequences of the feline and canine Bsep were as-
sembled and the predicted protein sequence was derived
from the open reading frame.
Hepatic mRNA expression of feline and canine Bsep
(Abcb11)
The expression of Bsep cDNA in feline and canine liver
samples was evaluated by RT-PCR using SYBR Green
Supermix (Bio-Rad, CA, USA) and species-specific prim-
ers (Table 1) and gel electrophoresis. After a hot start of
95°C for 3 min, PCR was performed at 95°C for 20 s, at
55-65°C for 30 s, and at 72°C for 30 s for a total of
40 cycles.
Cloning of cDNA encoding Bsep/BSEP (Abcb11/ABCB11)
To isolate the full-length Bsep encoding sequence, a PCR
was performed as described before with primers specific
for each animal species. Primers are given in Table 1. For
the cat the set of primers consisted of the forward and
reverse primers FullBsep_felinef and FullBsep_feliner
respectively. For the dog, the forward primer FullBsep_
caninef and the reverse primer FullBsep_caniner was used.
The product obtained from this first PCR was used for a
second PCR, to attach AttB1-primers used for the cloning
procedure of Bsep into the membrane vesicles of HEK293
cells (Gateway, Invitrogen, CA, USA). The conditions of
the PCR analysis were similar as described above, except
for a final concentration of approximately 9% DMSO in
the PCR mixture, an annealing temperature of 70°C and
a total of 10 cycles. AttB1-primers used for this second
PCR are given in Table 1. A PCR reaction to obtain the
full-length human BSEP encoding sequence was per-
formed on the ORFEXPRESS™-ABCB11 vector (LabOmics,
GC-H5308) with the forward primer FullBSEP +AttB1_
humanf and the reverse primer FullBSEP +AttB1_humanr.
After obtaining the BSEP-AttB-product of each species,
the product was purified with 30% polyethylene glycol
(PEG) 8000/30 mM MgCl2 to remove the surplus of
primers.
The pENTR221-BSEP vectors for all species were con-
structed by performing a BP-reaction. Toxicity problems
due to a TATAAT sequence in the human BSEP gene
[12] were circumvented by introducing a silent mutation
at base pair position 81 (AAT →AAC). The sequences
of the BSEP/Bsep genes within the pENTR221-BSEP
vectors were confirmed, and an LR reaction was per-
formed with the pENTR221 vectors containing the
feline, canine and human Bsep/BSEP and with the des-
tination vector BacMam-VSV-DEST. Enhanced yellow
fluorescent protein (eYFP) was used as a negative con-
trol, as described previously [13]. Eventually, the expres-
sion vectors BacMam-VSV-EX-BSEP were constructed
for all species.
Preparation of membrane vesicles of HEK293 cells
expressing Bsep/BSEP
After production of recombinant baculo-viruses following
the Bac-to-Bac manual, HEK293 cells were transfected
and membrane vesicles were isolated as previously de-
scribed [13]. Briefly, transfected HEK293 cells were lysed
with a hypotonic buffer and centrifuged at 100.000 g. Pel-
lets were resuspended in an isotonic buffer and the mem-
brane vesicles were isolated with spinning steps of 4000 g
and 100.000 g. After passing the membranes through a 27-
gauge needle for 25 times, protein concentrations were
determined with the Bio-Rad protein assay kit (Bio-Rad,
CA, USA). Presence of BSEP protein in the vesicles was
demonstrated by Western blotting using a polyclonal anti-
body against rat Bsep, which was a generous gift from
Dr. B. Stieger (University of Zürich, Switzerland). The
antibody was produced in rabbits against the last 13
amino acids of rat Bsep (amino acid sequence: AYYKL-
VITGAPIS) [12] and a secondary goat-anti-rabbit HRP
antibody. As a control, Western blotting was first per-
formed on liver tissue of rats, cats and dogs. Protein con-
centrations were determined according to Bradford [14].
Functional characterization of Bsep/BSEP-containing
membrane vesicles
The membrane vesicles (7.5 μg protein) were incubated
in a 30 μL transport mixture with a final concentration
of 10 mM Tris Base (pH 7.4), 250 mM sucrose, 10 mM
MgCl2, 4 mM adenosine triphosphate (ATP) or adeno-
sine monophosphate (AMP), 1 μM [3H]taurocholic acid
(TCA), with or without an inhibitor, in 96-well plates at
37°C. For the concentration-dependent curves 0.15 μCi
[3H]TCA, 0.05 μCi [3H]GCA and 0.3μCi [3H]CA was
used, supplemented with unlabeled TCA, GCA or CA
respectively. The reaction was stopped by placing the
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96-well plate on ice-water and by adding 150 μL ice-cold
washing buffer (10 mM Tris Base pH 7.4, 250 mM su-
crose). The reaction mixture was transferred to a 96-
well Multi-Screen HTS filter plate (Millipore, Ireland)
and the total mixture was filtered by means of a
Multi-Screen HTS vacuum manifold filtration device
(Millipore, Etten-Leur, The Netherlands). The filters
were washed twice with 200 μL washing buffer, where-
after they were separated from the plate. Two ml scintil-
lation fluid was added and the radioactivity remaining
on the filter was measured by a liquid scintillation
analyzer (Tri-carb 2900 TR, Packard). ATP-dependent
transport was calculated by subtracting uptake in pres-
ence of AMP from that in presence of ATP. The incuba-
tion period was checked for linearity in transport rate.
Concentration-dependent BSEP transport rates were fit-
ted according to Michaelis-Menten enzyme kinetics and
Km values were calculated by means of GraphPad Prism
6.01 software (San Diego, California, USA).
Statistical analysis
Data were expressed as means ± SD of at least three in-
dependent experiments with samples performed in du-
plicate. Data were analyzed using a one-way or two-way
analysis of variance (ANOVA) followed by the Bonfer-
roni post-hoc test (GraphPad Prism 6.01 software, San
Diego, California, USA) with P < 0.05 denoting a signifi-
cant difference.
Results
cDNA sequence and predicted amino acid sequence of
feline and canine Bsep
The cDNA coding sequences of feline and canine Bsep
were obtained as described in the Methods section and
demonstrated a high level of homology with an identity
of 91.2%. The feline cDNA sequence has been submitted
to the NCBI database [NCBI accession number KF601333].
The open reading frame (ORF) of the obtained canine
Bsep sequence was highly identical (99.8%) to the previ-
ously reported sequence by Yabuuchi et al. [11], with only
a few non-coding differences in the cDNA sequence
resulting in a completely similar amino acid sequence. Fe-
line Bsep cDNA was 89.3% identical to human BSEP se-
quence [NCBI accession number NM_003742]. In this
respect, dogs also share 89.3% identity with human BSEP.
The amino acid sequence deduced from the ORF of
ABCB11 of the different species is shown in Figure 1.
Differences in amino acids between human, dogs and
cats are displayed in small black borders. The amino
acid sequences showed a similarity of 92.3% between
cats and dogs. Cat Bsep is 88.9% identical to the human
protein, and dog Bsep 89.6%. The twelve transmem-
brane domains, the Walker A and B motifs and the
signatures were highly identical between species. The
major differences in amino acid pattern were located
halfway the ORF sequence (ORF position 661–684),
in the “linker domain” of the first nucleotide-binding
domain, over a range of 23 amino acids. Moreover,
both feline and canine ORF sequences contained four
amino acids more than the human BSEP ORF in this
region.
Bsep/BSEP gene and protein expression in liver tissue
samples
Presence of Bsep mRNA in pooled liver samples from cats
and dogs was demonstrated by PCR analyses (Figure 2).
The bands of Bsep mRNA can only be compared qualita-
tively, but they appeared to be of similar density. Presence
of Bsep protein in liver tissue was demonstrated by
Western blotting using a rabbit anti-rat Bsep antibody.
The expression of Bsep was observed in livers from rat,
dog and cat (data not shown).
Bsep/BSEP protein expression in membrane vesicles
prepared from native and Bsep/BSEP-overexpressing
HEK293 cells
The presence of Bsep/BSEP in membrane vesicles pre-
pared from HEK293 cells overexpressing feline, canine
and human Bsep/BSEP was confirmed by Western blot-
ting (Figure 3). No staining was seen in the vesicles serving
as negative control that were prepared from mock-
transduced HEK293 cells with eYFP, which indicates that
both bands in the Western blot (lane C, D, and E) are spe-
cific. The double band can be explained by posttransla-
tional modifications (most likely N-glycosylation) of the
protein as previously discussed by Gerloff et al. [15].
Vesicular uptake studies
Vesicular uptake of tritium-labeled TCA, GCA and CA
was demonstrated for all samples containing Bsep/BSEP
proteins, while uptake into membrane vesicles prepared
from mock-transduced HEK293 cells did not exceed
background activity (data not shown). The vesicular
uptake was ATP-dependent and the rate of uptake was
time-dependent (data not shown). To be in the linear
range of the uptake rate, samples were incubated for
5 minutes to assess the transport kinetics of TCA and
7.5 minutes to assess the transport kinetics of GCA and CA.
The rate of bile salt uptake into the vesicles was satur-
able and the data could be described according to
Michaelis-Menten kinetics (Figures 4 and 5). Km values
obtained for each bile acid from nonlinear regression
analysis were compared between species (Table 2). There
were no differences in Km values of each bile acid be-
tween the vesicles prepared from cells overexpressing
Bsep/BSEP of the different species. Within species, the
Km value for uptake of CA by the vesicles overexpressing
feline or canine Bsep was higher than the corresponding
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Km value for TCA uptake. The feline Bsep also had a
lower affinity for CA than for GCA.
Differences in maximum rate of ATP-dependent uptake
were seen between uptake of CA versus TCA and GCA.
Variations in the maximum rate of ATP-dependent uptake
were also seen in the uptake of the bile acids between the
species (Figure 5).
The inhibitory effects of three model Bsep inhibitors
were subsequently determined on TCA uptake in the
membrane vesicles. Cyclosporine A, troglitazone and ke-
toconazole decreased the uptake of TCA by vesicles pre-
pared from the cells overexpressing Bsep/BSEP of the
different species and the data were fitted by nonlinear
Figure 1 Alignment of human, dog and cat amino acid sequences of BSEP/Bsep ORF. Differences in amino acid pattern relative to the
human BSEP sequence are given in black borders. Transmembrane domains were predicted by Yabuuchi et al. [11] for the dog, and are given in
red borders for all species. Walker A is given in purple borders, Walker B in green borders and Signature C in yellow borders. The region of highly
different amino acid sequences is given in a blue border.
Figure 2 Bsep product of canine and feline liver tissue using
primers BSEP_Lf and BSEP_Lr on a 1.8% agarose gel stained
with ethidium bromide. A: BenchTop 100 bp DNA Ladder
(Promega, USA); B: canine Bsep; C: feline Bsep.
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regression to a one-site competition model (Figure 6).
Inhibitory potencies, as given by the IC50 values, were
all in the micromolar range and the potency of each
compound did not differ significantly between species
(Table 3).
Discussion
The aim of this study was to characterize and compare
the function of feline bile acid efflux transporter Bsep
with canine and human Bsep/BSEP with respect to
endogenous bile acids and typical drug inhibitors. To
this end, membrane vesicles isolated from genetically
engineered cells overexpressing Bsep/BSEP of the differ-
ent species were made. To our knowledge, this is the
first study in which feline Bsep has been cloned and
characterized.
The cDNA sequence of the ORFs of feline, canine
and human Bsep/BSEP showed a high similarity be-
tween the species. Analysis of the translated protein
sequences revealed that the twelve transmembrane
domains, which are thought to be responsible for sub-
strate specificity, and the Walker A and Walker B mo-
tifs, which are needed for binding and hydrolyzation of
ATP, appeared to be highly identical. A more divergent
part of the protein was observed in the linker region
from amino acid 661 to 684, where feline and canine
Bsep contains four additional amino acids compared to
the human BSEP. The linker region may have a regula-
tory role in the rate of ATP hydrolysis, as has been
described for P-glycoprotein/ABCB1 [16], or it could
mediate the turnover of the ABC transporter [17].
Amino acid differences in the linker region could also
relate to species differences in post-transcriptional
regulation of BSEP/Bsep.
The presence of BSEP/Bsep protein in the mem-
brane vesicles that were prepared from HEK293 cells
overexpressing the transporter was confirmed by Western
blotting. Although differences in BSEP/Bsep staining
intensity were observed between vesicle preparations of
Figure 3 Western Blot of membrane vesicles over-expressing
cat, dog and human Bsep/BSEP. A: Precision Plus Protein Dual
Color Marker (Bio-rad Laboratories); B: eYFP (control); C: Bsep cat;
D: Bsep dog; E: BSEP human. In lanes B, C, D, and E equal amounts
of total protein were loaded.
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Figure 4 ATP-dependent transport of TCA, CA and GCA in membrane vesicles (7.5 μg protein) expressing BSEP/Bsep of human (▲),
dogs (□), and cats (○). Vesicles were incubated in 10 mMTris Base buffer (pH 7.4) containing 250 mM Sucrose, 10 mM MgCl2 and 4 mM ATP or
AMP, at 37°C for 5 min (TCA) or 7.5 min (CA and GCA). ATP-dependent transport was calculated by subtracting transport in presence of AMP from
that in presence of ATP. Curves were fitted by GraphPad Prism 6.01 software (San Diego, California, USA) and Vmax was calculated. Measurements were
performed in duplicate in at least three independent experiments. The mean of the duplicates of each experiment was transformed as a relative activ-
ity to the Vmax (=100%). Each value in the graph is the mean ± SD of the relative activities of three independent experiments.
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the different species, a quantitative estimate of trans-
port protein abundance could not be made. The used
antibody was developed against the last 13 amino
acids of the ORF of rat Bsep and differences in affin-
ity for the proteins of the different species could be
expected. The terminal 13 amino acids of rat Bsep are
exactly the same for feline Bsep. Canine Bsep differs
one amino acid and human BSEP two amino acids
from rat. Variations in transporter abundance in the
vesicle preparations may have occurred and a direct
comparison of maximum transport activities of BSEP/
Bsep between the different species can therefore not
be made. However, we observed in different transduc-
tions and vesicle preparations consistently lower Vmax
values of cat Bsep for all tested bile acids compared to
human and dog BSEP/Bsep. Moreover, in spite of a low
staining intensity for human BSEP compared to canine
and feline Bsep, we consistently found the highest Vmax
for human BSEP for all substrates compared to the
other species.
The functional studies demonstrated that TCA, GCA
and CA were substrates of BSEP/Bsep in all three spe-
cies, showing saturable transport kinetics. Km values
were in the same range as reported by different groups
for human BSEP and rat Bsep in different expression
systems [6]. In all species there was a tendency to a
higher affinity of Bsep for TCA than GCA, and a higher
affinity for GCA than CA. The same order of affinity of
the bile acids TCA and GCA was previously noted for
human BSEP [12,18]. The lower affinity and maximum
transport rate of CA compared to TCA and GCA for fe-
line and canine Bsep, is in accordance with a relatively
lower amount of unconjugated bile salts in bile of these
species. The conjugated bile acid TCA is a model sub-
strate for BSEP, commonly used in in vitro functional
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Figure 5 ATP-dependent transport of TCA (○), GCA (▲) and CA (□) in membrane vesicles (7.5 μg protein) expressing human, dog and
cat BSEP/Bsep. Vesicles were incubated in 10 mMTris buffer (pH 7.4) containing 250 mM Sucrose, 10 mM MgCl2 and 4 mM ATP or AMP, at 37°C
for 5 min (TCA) or 7.5 min (CA and GCA). ATP-dependent transport was calculated by subtracting transport in presence of AMP from that in pres-
ence of ATP. Curves were fitted by using GraphPad Prism 6.01 software (San Diego, California, USA). Measurements were performed in duplicate
in three independent experiments and are given in pmol/mg protein/min. Each value in the graph is the mean ± SD of three
independent experiments.
Table 2 Km values for TCA, GCA and CA of human, dog
and cat BSEP/Bsep containing membrane vesicles
(7.5 μg protein)
Km (μM)
Human Dog Cat
TCA 4.1 ± 0.5 3.4 ± 0.3 7.5 ± 0.7
GCA 9.0 ± 2.0 19.3 ± 3.5 13.4 ± 2.0
CA 11.3 ± 4.3 27.2 ± 3.2a 41.2 ± 11.3b,c
asignificantly different from TCA in dogs.
bsignificantly different from TCA in cats.
csignificantly different from GCA in cats.
Km/Vmax curves were fitted by GraphPad Prism 6.01 software (San Diego,
California, USA) and Km was calculated. Measurements were performed in
duplicate in at least three independent experiments and mean Km ± SD are
given in the table. Statistical significance was determined by a two-way
ANOVA followed by the Bonferroni post-hoc test. P < 0.05 indicates a
significant difference.
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studies, although in man bile acids are mainly conju-
gated to glycine and only to a minor extent to taurine.
This is in contrast to carnivore species, like cat and dog,
in which bile acids are almost exclusively conjugated to
taurine with TCA as the major bile acid in both species
[19–21]. Since protein sequence and function of Bsep
appeared to be highly conserved among human, dog and
cat, inter-species variation in the constitution of
conjugated bile acids must be more related to the avail-
ability of co-substrates or enzymes for conjugation.
The inhibitory potency of the model inhibitors
cyclosporine A, troglitazone and ketoconazole was
characterized against TCA uptake into BSEP/Bsep
containing membrane vesicles. All three substances
potently inhibited TCA uptake without significant
species differences. A comparable inhibitory potential
of troglitazone was found previously for human and
canine BSEP/Bsep [11,18].
Conclusions
The structure and functional characteristics of cat Bsep
appeared to be very similar to dog and human Bsep/
BSEP, indicating that the properties of this transporter
have been highly preserved among the different species.
The methods and results of this study can be used as an
in vitro model for the assessment of interactions of
drugs and other substances with feline and canine Bsep,
which is suitable to study the risk of drug-induced cho-
lestasis in these species in more detail.
Inhibition of BSEP by drugs has been related to chole-
stasis and subsequent drug-induced liver injury in man
and could also be a mechanism in cholestasis and liver
disease in veterinary relevant animal species.
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Figure 6 Inhibition of cyclosporine A, troglitazone and ketoconazole on the uptake of 1 μM [3H]TCA in membrane vesicles (7.5 μg
protein) expressing human (▲), dog (□) and cat (○) BSEP/Bsep. Vesicles were incubated in 10 mMTris Base buffer (pH 7.4) containing
250 mM Sucrose, 10 mM MgCl2 and 4 mM ATP or AMP, at 37°C for 5 min. ATP-dependent transport was calculated by subtracting transport in
presence of AMP from that in presence of ATP. Inhibition curves were fitted by using GraphPad Prism 6.01 software (San Diego, California, USA)
and values are expressed as mean ± SD of percentage uptake of fourindependent experiments.
Table 3 Inhibitory potency of cyclosporine A, troglitazone
and ketoconazole against 1 μM [3H]TCA uptake into
membrane vesicles (7.5 μg protein) expressing human,
dog and cat BSEP/Bsep
IC50 (μM)
Human Dog Cat
Cyclosporine A 7.8 ± 1.2 3.8 ± 0.2 6.0 ± 0.8
Troglitazone 20.9 ± 2.9 23.9 ± 2.5 13.6 ± 4.2
Ketoconazole 20.6 ± 1.1 34.2 ± 2.0 41.8 ± 6.6
Inhibition curves were fitted by using GraphPad Prism 6.01 software (samples
without inhibitor were set on 100%). [3H]TCA uptake in presence of ATP was
corrected for uptake in presence of AMP. Measurements were performed in
duplicate in four independent experiments. Statistical significance was
determined by one-way ANOVA followed by the Bonferroni post-hoc test with
P < 0.05 denoting a significant difference. No significant differences were
found between the different species.
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